Gastric cancer remains a common gastrointestinal malignancy and a major contributor to the global cancer burden.Conventional radical surgery has long relied on organ resection and lymph node dissection as its central paradigm, providing an important foundation for the treatment of locally advanced gastric cancer.Super minimally invasive surgery (SMIS) moves beyond a simple resection-oriented logic by emphasizing preservation of anatomical integrity, maintenance of inherent physiological function, and precise eradication of the lesion.This concept offers a potential direction for the evolution of gastric cancer intervention.Meanwhile, gastric cancer should not be regarded solely as a local lesion; its occurrence, progression, and therapeutic response are jointly shaped by the immune microenvironment, cellular lineage states, and molecular heterogeneity. From the perspective of the systemic nature of tumors, this article integrates evidence from precision classification and evolving treatment strategies, analyzes differences in the immune microenvironment and systemic immune status across early, locally advanced, and advanced gastric cancer, and discusses the sequential logic of neoadjuvant therapy followed by SMIS-based local precise eradication. The aim is to outline an integrated treatment model combining organ preservation, lesion eradication, immune reconstruction, and systemic regulation, thereby providing a theoretical and practical reference for individualized and function-oriented management of gastric cancer.